Immunovia Financial Statements From 2010 to 2024
| IMMNOV Stock | SEK 0.63 0.01 1.61% |
Check Immunovia Publ financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovia Publ's main balance sheet or income statement drivers, such as , as well as many indicators such as . Immunovia financial statements analysis is a perfect complement when working with Immunovia Publ Valuation or Volatility modules.
Immunovia |
Immunovia publ AB Company Operating Margin Analysis
Immunovia Publ's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Immunovia Publ Operating Margin | (201.30) % |
Most of Immunovia Publ's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovia publ AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Immunovia publ AB has an Operating Margin of -201.2993%. This is much higher than that of the Healthcare sector and 217.71% higher than that of the Diagnostics & Research industry. The operating margin for all Sweden stocks is notably higher than that of the company.
Immunovia publ AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunovia Publ's current stock value. Our valuation model uses many indicators to compare Immunovia Publ value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovia Publ competition to find correlations between indicators driving Immunovia Publ's intrinsic value. More Info.Immunovia publ AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunovia Publ by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunovia Publ's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Immunovia Publ Financial Statements
Immunovia Publ stakeholders use historical fundamental indicators, such as Immunovia Publ's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunovia Publ investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immunovia Publ's assets and liabilities are reflected in the revenues and expenses on Immunovia Publ's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immunovia publ AB. Please read more on our technical analysis and fundamental analysis pages.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Immunovia Stock
Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.